SCHEMBL1472271

SCHEMBL1472271

Brc1ccc2nc(-c3ccc4ccccc4c3)cn2c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.63
RAB9A P51151 6/20 0.63
ALDH1A1 P00352 5/20 0.63
SMN1; SMN2 Q16637 3/20 0.63
MEN1 O00255 2/20 0.63
KMT2A Q03164 2/20 0.63
NFKB1 P19838 2/20 0.63
NFKB2 Q00653 2/20 0.63
RELA Q04206 2/20 0.63
LMNA P02545 1/20 0.63
APP P05067 5/20 0.62
CLK1 P49759 1/20 0.55
DYRK1A Q13627 1/20 0.55
KDM4E B2RXH2 4/20 0.55
POLB P06746 1/20 0.55
PAX8 Q06710 1/20 0.55
MAPT P10636 1/20 0.52
ALDH1A3 P47895 5/20 0.51
ALDH1A2 O94788 1/20 0.51
HRH3 Q9Y5N1 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL974462 0.88 ALDH1A1 (0.63) NPC1RAB9AALDH1A1SMN1; SMN2MEN1
SCHEMBL1691846 0.83 NPC1 (0.68) NPC1RAB9AALDH1A1SMN1; SMN2MEN1
SCHEMBL5302309 0.83 ALDH1A3 (0.75) NPC1RAB9AALDH1A1SMN1; SMN2MEN1
SCHEMBL970456 0.82 ALDH1A3 (0.69) NPC1RAB9AALDH1A1SMN1; SMN2MEN1
SCHEMBL7605200 0.82 NPC1 (0.77) NPC1RAB9AALDH1A1SMN1; SMN2MEN1
SCHEMBL13325714 0.82 RAB9A (0.69) NPC1RAB9AALDH1A1SMN1; SMN2MEN1
Bromide SCHEMBL1691457 0.80 NPC1 (0.75) NPC1RAB9AALDH1A1SMN1; SMN2MEN1
SCHEMBL29614084 0.80 RAB9A (0.68) NPC1RAB9AALDH1A1SMN1; SMN2MEN1
SCHEMBL13325743 0.80 RAB9A (0.68) NPC1RAB9AALDH1A1SMN1; SMN2MEN1
SCHEMBL12692455 0.79 RAB9A (0.97) NPC1RAB9AALDH1A1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7915284-B2 2-aryl-6-phenylimidazo[1,2-a]pyridine derivatives, preparation thereof and therapeutic use thereof SANOFI-AVENTIS (FR) 2011-03-29 US disclosed
EP-2069342-B1 2-ARYL-6-PHENYLIMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2010-05-12 EP disclosed
US-20090253735-A1 2-ARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253735-A1 2-ARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF NCOR1, NR4A2, NR4A3 NPC1 781/4885RAB9A 4133/4885ALDH1A1 1788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.